

Roxana Mehran, Mscai

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/5050958/publications.pdf>

Version: 2024-02-01

303
papers

54,576
citations

4960
84
h-index

1190
228
g-index

306
all docs

306
docs citations

306
times ranked

26038
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside. Cardiovascular Research, 2023, 119, 631-646.	3.8	23
2	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal, 2022, 43, e17-e25.	2.2	92
3	Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 648-659.	3.0	11
4	Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI. Journal of Thrombosis and Thrombolysis, 2022, 53, 380-389.	2.1	4
5	Bleeding avoidance strategies in percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 117-132.	13.7	71
6	Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 492-502.	3.0	22
7	Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction. Journal of Thrombosis and Thrombolysis, 2022, 53, 20-29.	2.1	8
8	Clinical outcomes according to lesion complexity in high bleeding risk patients treated with 1â€month dual antiplatelet therapy following <scp>PCI</scp>: Analysis from the <scp>Onyx ONE</scp> clear study. Catheterization and Cardiovascular Interventions, 2022, 99, 583-592.	1.7	3
9	Sex Differences in Cardiovascular Research: A Scientometric Analysis. Journal of the American Heart Association, 2022, 11, e021522.	3.7	4
10	Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization. Nature Reviews Cardiology, 2022, 19, 195-208.	13.7	34
11	The year in cardiovascular medicine 2021: interventional cardiology. European Heart Journal, 2022, 43, 377-386.	2.2	3
12	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. Journal of the American College of Cardiology, 2022, 79, e21-e129.	2.8	561
13	SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 557-567.	3.0	20
14	Prolonged dual antiplatelet therapy in selected patients with acute coronary syndrome. Catheterization and Cardiovascular Interventions, 2022, 99, 114-115.	1.7	0
15	Impact of Race/Ethnicity on Long Term Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stents. American Journal of Cardiology, 2022, , .	1.6	0
16	Evidence base for the management of women with non-ST elevation acute coronary syndrome. Heart, 2022, 108, 1682-1689.	2.9	13
17	Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris. American Journal of Cardiology, 2022, 168, 47-54.	1.6	4
18	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, CIR0000000000001038.	1.6	177

#	ARTICLE	IF	CITATIONS
19	SCAI Expert Consensus Statement on Sex-Specific Considerations in Myocardial Revascularizationâ€”A Powerful Reminder and Call to Action. , 2022, , 100006.		0
20	SCAI Expert Consensus Statement on Sex-Specific Considerations in Myocardial Revascularization. , 2022, 1, 100016.		2
21	Prognostic Value of Baseline Inflammation in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention. Canadian Journal of Cardiology, 2022, 38, 792-800.	1.7	2
22	Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acuteâ€”Coronaryâ€”Syndromes. JACC: Cardiovascular Interventions, 2022, 15, 268-277.	2.9	62
23	The new European Society of Cardiology/European Association for Cardio-Thoracic Surgery recommendations for transcatheter aortic valve intervention are too restrictive. European Heart Journal, 2022, 43, 2751-2752.	2.2	4
24	Sex Differences in Outcomes After Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Left Main Disease: From the DELTA Registries. Journal of the American Heart Association, 2022, 11, e022320.	3.7	5
25	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 707-716.	3.0	5
26	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. EuroIntervention, 2022, 17, 1330-1339.	3.2	5
27	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. Circulation, 2022, 145, 847-863.	1.6	28
28	Perioperative Management of P2Y12 Inhibitors in Patients Undergoing Cardiac Surgery within 1 Year of PCI. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	3.0	2
29	Elderly patients with acute myocardial infarction: Targeted or complete revascularization?. Catheterization and Cardiovascular Interventions, 2022, 99, 979-980.	1.7	2
30	Readmission in Patients With ST-Elevation Myocardial Infarction in 4 Age Groups (<45, >45 to) Tj ETQq0 0 0 rgBT /Overlap 10 Tf 5	1.6	1
31	Impact of Small Valve Size on 1-Year Outcomes After Transcatheter Aortic Valve Implantation in Women (from the WIN-TAVI Registry). American Journal of Cardiology, 2022, 172, 73-80.	1.6	4
32	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS120009495.	3.9	4
33	The year in cardiovascular medicine 2021: interventional cardiology. Cardiologia Croatica, 2022, 17, 59-72.	0.0	1
34	Timing of Stent Thrombosis After 1-Month Discontinuation of Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2022, 79, 1963-1965.	2.8	0
35	A Biomarkerâ€”Enhanced Model for Prediction of Acute Kidney Injury and Cardiovascular Risk Following Angiographic Procedures: CASABLANCA AKI Prediction Substudy. Journal of the American Heart Association, 2022, 11, e025729.	3.7	4
36	Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. Journal of the American College of Cardiology, 2022, 80, 63-88.	2.8	25

#	ARTICLE	IF	CITATIONS
37	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 829-844.	13.7	30
38	Invasive Versus Medical Management in Patients With Chronic Kidney Disease and Non-ST-Segment Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	5
39	Coronary In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2022, 80, 348-372.	2.8	72
40	Subjective angina or myocardial ischaemia to justify PCI? Never mistake the finger for the moon. <i>European Heart Journal</i> , 2022, 43, 3145-3147.	2.2	2
41	Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1111-1119.	1.7	2
42	Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI : TWILIGHT-SYNERGY. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 63-71.	1.7	6
43	Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 797-804.	1.7	4
44	One-year outcomes of patients undergoing complex percutaneous coronary intervention with three contemporary drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1341-1351.	1.7	5
45	Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management. <i>Nature Reviews Cardiology</i> , 2021, 18, 37-57.	13.7	42
46	Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E704-E715.	1.7	8
47	Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2021, 42, 308-319.	2.2	90
48	Prevalence, predictors, and outcomes of patient prosthesis mismatch in women undergoing <scp>TAVI</scp> for severe aortic stenosis: Insights from the <scp>WIN-TAVI</scp> registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 516-526.	1.7	17
49	Pregnancy during cardiology training: a call to action. <i>Heart</i> , 2021, 107, 1018-1019.	2.9	2
50	Radial versus femoral access for coronary interventions: An updated systematic review and meta-analysis of randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1387-1396.	1.7	42
51	One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 309-320.	2.6	2
52	Women and Cardiac Disease: A Special Issue. <i>International Journal of Cardiovascular Sciences</i> , 2021, 34, 338-339.	0.1	0
53	Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction: Bleeding Avoidance First and Foremost. <i>Journal of the American Heart Association</i> , 2021, 10, e019889.	3.7	1
54	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 444-456.	2.9	27

#	ARTICLE	IF	CITATIONS
55	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 583-596.	1.6	119
56	Aspirin-free strategies: a framework to reassess the role of dual antiplatelet therapy after percutaneous coronary intervention. <i>European Heart Journal</i> , 2021, 42, 2710-2711.	2.2	1
57	Temporal Trends in the Proportion of Women Physician Speakers at Major Cardiovascular Conferences. <i>Circulation</i> , 2021, 143, 755-757.	1.6	7
58	Gender Issues in Italian Catheterization Laboratories: The Genderâ€CATH Study. <i>Journal of the American Heart Association</i> , 2021, 10, e017537.	3.7	4
59	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 1215-1223.	1.6	9
60	Patients with COVID â€19 who experience a myocardial infarction have complex coronary morphology and high inâ€hospital mortality: Primary results of a nationwide angiographic study. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E370-E378.	1.7	13
61	Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation. <i>JAMA Cardiology</i> , 2021, 6, 410.	6.1	52
62	Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. <i>European Heart Journal</i> , 2021, 42, 1825-1857.	2.2	342
63	The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. <i>Lancet, The</i> , 2021, 397, 2385-2438.	13.7	530
64	Current state-of-the-art antiplatelet and anticoagulation therapy in diabetic patients with coronary artery disease. <i>Future Cardiology</i> , 2021, 17, 521-534.	1.2	3
65	Impact of anemia on shortâ€term outcomes after TAVR : A subgroup analysis from the BRAVO â€3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E870-E880.	1.7	2
66	P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2021, 373, n1332.	6.0	144
67	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E908-E917.	1.7	7
68	Sexual Harassment, Victim Blaming, andâ€The Potential Impact on Women in Cardiology. <i>JACC: Case Reports</i> , 2021, 3, 978-981.	0.6	2
69	Sexâ€Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. <i>Journal of the American Heart Association</i> , 2021, 10, e021965.	3.7	23
70	Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. <i>New England Journal of Medicine</i> , 2021, 385, 2150-2160.	27.0	144
71	Single antiplatelet therapy after transcatheter aortic valve implantation: clarity on existing data. <i>European Heart Journal</i> , 2021, 42, 3203-3204.	2.2	1
72	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , 2021, 42, 4683-4693.	2.2	18

#	ARTICLE	IF	CITATIONS
73	Types of myocardial injury and mid-term outcomes in patients with COVID-19. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 438-446.	4.0	28
74	Stick to the guidelines or clinical judgment: A toss up?. International Journal of Cardiology, 2021, 338, 83-84.	1.7	1
75	Sex-Related Differences in the Prevalence and Prognostic Value of the Academic Research Consortium for High Bleeding Risk Criteria. Circulation: Cardiovascular Interventions, 2021, 14, e010392.	3.9	6
76	First and recurrent events in the ISCHEMIA trial: two sides of the same coin. European Heart Journal, 2021, , .	2.2	2
77	3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. JACC: Cardiovascular Interventions, 2021, 14, 1870-1883.	2.9	56
78	Evaluation of Cerebral Thromboembolism After Transcatheter Aortic Valve Replacement (EARTH TAVR): A Serial Magnetic Resonance Imaging Evaluation as Substudy of the GALILEO Trial. Circulation: Cardiovascular Interventions, 2021, 14, e011074.	3.9	1
79	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. European Heart Journal, 2021, 42, 4624-4634.	2.2	54
80	Interventions in Ischemic Heart Disease. , 2021, , 93-108.		0
81	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. European Heart Journal, 2021, 42, 339-351.	2.2	57
82	Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. Circulation, 2021, 143, 479-500.	1.6	132
83	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. Circulation, 2021, 144, 1323-1343.	1.6	35
84	Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk. Journal of the American College of Cardiology, 2021, 78, 1968-1986.	2.8	11
85	Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2021, 78, 2060-2072.	2.8	39
86	A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. Lancet, The, 2021, 398, 1974-1983.	13.7	69
87	Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. Journal of the American Heart Association, 2021, 10, e023143.	3.7	0
88	A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. New England Journal of Medicine, 2020, 382, 120-129.	27.0	362
89	Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. New England Journal of Medicine, 2020, 382, 130-139.	27.0	194
90	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation, 2020, 141, 781-783.	1.6	80

#	ARTICLE	IF	CITATIONS
91	Impact of stent diameter on outcomes following percutaneous coronary intervention with second-generation drug-eluting stents: Results from a large single-center registry. Catheterization and Cardiovascular Interventions, 2020, 96, 558-564.	1.7	6
92	Trends and Outcomes of Intravascular Imaging-guided Percutaneous Coronary Intervention in the United States. Critical Pathways in Cardiology, 2020, 19, 69-74.	0.5	8
93	Edwards SAPIEN Versus Medtronic Aortic Bioprosthesis in Women Undergoing Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). American Journal of Cardiology, 2020, 125, 441-448.	1.6	9
94	Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial. Catheterization and Cardiovascular Interventions, 2020, 96, E377-E386.	1.7	5
95	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. Thrombosis and Haemostasis, 2020, 120, 348-362.	3.4	13
96	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. European Heart Journal, 2020, 41, 3533-3545.	2.2	93
97	Impact of High-Density Lipoprotein Levels on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2020, 137, 1-6.	1.6	0
98	Excimer laser coronary atherectomy for uncrossable coronary lesions. A multicenter registry. Catheterization and Cardiovascular Interventions, 2020, 98, 1241-1249.	1.7	13
99	One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. Circulation: Cardiovascular Interventions, 2020, 13, e009565.	3.9	49
100	Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2020, 9, e017212.	3.7	52
101	Drug-eluting stents in diabetic patients: Are we still treading water?. Catheterization and Cardiovascular Interventions, 2020, 96, 253-254.	1.7	2
102	Characterization of Myocardial Injury in Patients With COVID-19. Journal of the American College of Cardiology, 2020, 76, 2043-2055.	2.8	303
103	Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. Journal of the American College of Cardiology, 2020, 76, 1277-1286.	2.8	20
104	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2020, 76, 1468-1483.	2.8	35
105	Transcatheter aortic valve replacement in patients with <scp>end-stage</scp> renal disease: Is it better than nothing-good enough?. Catheterization and Cardiovascular Interventions, 2020, 96, 1110-1112.	1.7	0
106	Towards a standardized classification of cardiogenic shock: Will the new <scp>SCAI</scp> staging system translate into better clinical practice and research?. Catheterization and Cardiovascular Interventions, 2020, 96, 1348-1349.	1.7	1
107	Prognostic Impact of High-Sensitivity C-Reactive Protein in Patients Undergoing Percutaneous Coronary Intervention According to BMI. JACC: Cardiovascular Interventions, 2020, 13, 2882-2892.	2.9	6
108	Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review. Journal of the American Heart Association, 2020, 9, e018897.	3.7	23

#	ARTICLE	IF	CITATIONS
109	Treating Inflammation Prior to Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009127.	3.9	9
110	<sc>SCAI</sc> expert consensus statement on out of hospital cardiac arrest. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 844-861.	1.7	23
111	Comparison of One-Year Outcomes in Patients >75 Versus ≤75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry). <i>American Journal of Cardiology</i> , 2020, 127, 1-8.	1.6	5
112	1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1542-1547.	0.8	3
113	Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy. <i>JAMA Cardiology</i> , 2020, 5, 939.	6.1	21
114	Cardiovascular outcomes after percutaneous coronary intervention on bifurcation lesions with moderate to severe coronary calcium: A single-center registry study. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 98, 35-42.	1.7	7
115	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008226.	3.9	21
116	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 141, 1618-1627.	1.6	84
117	Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 298-308.	1.7	11
118	An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. <i>European Heart Journal</i> , 2020, 41, 3504-3520.	2.2	385
119	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 582.	6.1	71
120	Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. <i>Journal of the American College of Cardiology</i> , 2020, 75, 578-586.	2.8	66
121	Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2020, 382, 1208-1218.	27.0	207
122	Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 375-387.	2.9	55
123	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	13.7	87
124	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk. <i>Circulation</i> , 2020, 141, 891-901.	1.6	28
125	1-Year Clinical Outcomes of AllComersTreated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 820-830.	2.9	10
126	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2403-2413.	2.8	60

#	ARTICLE	IF	CITATIONS
127	Ticagrelor With or Without Aspirin After ComplexÂPCI. Journal of the American College of Cardiology, 2020, 75, 2414-2424.	2.8	122
128	Sexâ€Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patientâ€Level Pooled Analysis From 4 Postapproval Studies. Journal of the American Heart Association, 2020, 9, e014611.	3.7	12
129	Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. Journal of the American College of Cardiology, 2020, 75, 2711-2722.	2.8	139
130	Abluminus DES+ for the treatment of coronary artery disease in patients with diabetes mellitus. Future Cardiology, 2020, 16, 613-623.	1.2	5
131	Why stronger radiation safety measures are essential for the modern workforce. A perspective from EAPCI Women and Women as One. EuroIntervention, 2020, 16, 24-25.	3.2	4
132	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2019, 12, e007734.	3.9	6
133	Management of Antithrombotic Therapy in Atrial Fibrillation Patients UndergoingÂPCI. Journal of the American College of Cardiology, 2019, 74, 83-99.	2.8	126
134	Updated Expert Consensus Statement on Platelet Function and Genetic Testing forÂGuiding P2Y12 Receptor Inhibitor Treatment in Percutaneous CoronaryÂIntervention. JACC: Cardiovascular Interventions, 2019, 12, 1521-1537.	2.9	366
135	Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial. International Journal of Cardiology, 2019, 297, 22-29.	1.7	10
136	Ticagrelor Monotherapy After CoronaryÂStenting. Journal of the American College of Cardiology, 2019, 74, 2235-2237.	2.8	3
137	Complete Revascularization with Multivessel PCI for Myocardial Infarction. New England Journal of Medicine, 2019, 381, 1411-1421.	27.0	542
138	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. Circulation, 2019, 140, 1921-1932.	1.6	57
139	Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. New England Journal of Medicine, 2019, 381, 1820-1830.	27.0	523
140	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. New England Journal of Medicine, 2019, 381, 2032-2042.	27.0	683
141	Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. International Journal of Cardiology, 2019, 283, 67-72.	1.7	19
142	Predictors of mortality in patients with nonâ€Anterior STâ€segment elevation myocardial infarction: Analysis from the HORIZONSâ€AMI trial. Catheterization and Cardiovascular Interventions, 2019, 94, 172-180.	1.7	9
143	Impact of calcification on percutaneous coronary intervention: MACEâ€Trial 1â€year results. Catheterization and Cardiovascular Interventions, 2019, 94, 187-194.	1.7	36
144	Smallâ€vessel PCI outcomes in men, women, and minorities following platinum chromium everolimusâ€eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Postâ€Approval studies. Catheterization and Cardiovascular Interventions, 2019, 94, 82-90.	1.7	10

#	ARTICLE	IF	CITATIONS
145	Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1â€ month of dual antiplatelet therapy. American Heart Journal, 2019, 214, 134-141.	2.7	31
146	Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2019, 4, 747.	6.1	198
147	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal, 2019, 40, 2632-2653.	2.2	335
148	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2019, 140, 240-261.	1.6	428
149	Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVOâ€ randomized trial. Catheterization and Cardiovascular Interventions, 2019, 93, 1374-1381.	1.7	35
150	Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. International Journal of Cardiology, 2019, 287, 59-61.	1.7	8
151	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. New England Journal of Medicine, 2019, 380, 1509-1524.	27.0	833
152	Hope for the best, prepare for the worst: How to manage coronary perforations. Catheterization and Cardiovascular Interventions, 2019, 93, E255-E256.	1.7	2
153	Atrial fibrillation, with ACS and PCI: walking a tightrope. European Heart Journal, 2019, 40, 1563-1566.	2.2	5
154	Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. Journal of Thrombosis and Thrombolysis, 2019, 48, 42-51.	2.1	5
155	Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2019, 123, 1788-1795.	1.6	7
156	Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial). American Journal of Cardiology, 2019, 123, 1494-1500.	1.6	19
157	The link between anemia and adverse outcomes in patients with acute coronary syndrome. Expert Review of Cardiovascular Therapy, 2019, 17, 151-159.	1.5	10
158	Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis. European Heart Journal, 2019, 40, 1334-1340.	2.2	77
159	The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. American Heart Journal, 2019, 208, 81-90.	2.7	25
160	Sex Differences in the Pursuit of Interventional Cardiology as a Subspecialty Among Cardiovascular Fellows-in-Training. JACC: Cardiovascular Interventions, 2019, 12, 219-228.	2.9	49
161	Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. American Journal of Cardiology, 2019, 123, 709-716.	1.6	9
162	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2019, 12, e007411.	3.9	55

#	ARTICLE	IF	CITATIONS
163	Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention. <i>American Heart Journal</i> , 2019, 207, 10-18.	2.7	7
164	Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1124-1131.	1.7	22
165	Female-specific survival advantage from transcatheter aortic valve implantation over surgical aortic valve replacement: Meta-analysis of the gender subgroups of randomised controlled trials including 3758 patients. <i>International Journal of Cardiology</i> , 2018, 250, 66-72.	1.7	33
166	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Circulation</i> , 2018, 137, 961-972.	1.6	368
167	Equal sex-based outcomes in unprotected left main PCI: No advantage for men. <i>International Journal of Cardiology</i> , 2018, 253, 61-63.	1.7	1
168	1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1-12.	2.9	77
169	An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. <i>American Heart Journal</i> , 2018, 200, 17-23.	2.7	69
170	Bleeding Severity After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005542.	3.9	13
171	Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 626-634.	2.9	25
172	Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newer-generation DES: Findings from a large multiethnic registry. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 859-866.	1.7	69
173	Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006853.	3.9	17
174	1-Year Clinical Outcomes of All-Coroner Patients Treated With the Dual-Therapy COMBO Stent. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1969-1978.	2.9	21
175	Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1909-1916.	1.6	18
176	Women's Voices in Cardiology. <i>JAMA Cardiology</i> , 2018, 3, 676.	6.1	9
177	Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNeich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. <i>European Heart Journal</i> , 2018, 39, 2460-2468.	2.2	58
178	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496.	13.7	180
179	Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 754-765.	2.8	59
180	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1638-1646.	1.6	19

#	ARTICLE	IF	CITATIONS
181	Standardized End Point Definitions for Coronary Intervention Trials. <i>European Heart Journal</i> , 2018, 39, 2192-2207.	2.2	179
182	Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 629-637.	1.7	56
183	Impact of Diabetes Mellitus on Ischemic Events in Men and Women After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2017, 119, 1166-1172.	1.6	12
184	Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. <i>American Heart Journal</i> , 2017, 188, 73-81.	2.7	25
185	Percutaneous Coronary Intervention of Saphenous Vein Graft. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	35
186	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. <i>International Journal of Cardiology</i> , 2017, 243, 132-139.	1.7	11
187	Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	63
188	Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	14
189	Relation of Baseline Hemoglobin Levels and Adverse Events in Patients With Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage strategY and Harmonizing) Tj ETQq1 1 0.784314 rgBT /Over of Cardiology. 2017, 119, 1710-1716.	1.6	39
190	Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents. <i>International Journal of Cardiology</i> , 2017, 231, 61-67.	1.7	71
191	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor-Inhibiting Therapies. <i>Circulation</i> , 2017, 136, 1955-1975.	1.6	293
192	Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1846-1857.	2.8	58
193	Outcomes in Women and Minorities Compared With White Men 1 Year After Everolimus-Eluting Stent Implantation. <i>JAMA Cardiology</i> , 2017, 2, 1303.	6.1	46
194	Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. <i>International Journal of Cardiology</i> , 2017, 246, 20-25.	1.7	15
195	Thrombo-embolic prevention after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2017, 38, 3341-3350.	2.2	59
196	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 855.	6.1	25
197	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of) Tj ETQq1 1 0.784314 rgBT /Over 2017, 120, 904-910.	1.6	10
198	Reply. <i>American Journal of Cardiology</i> , 2017, 120, e33.	1.6	0

#	ARTICLE	IF	CITATIONS
199	The DELTA 2 Registry. JACC: Cardiovascular Interventions, 2017, 10, 2401-2410.	2.9	41
200	Outcomes After Successful Percutaneous Coronary Intervention of Calcified Lesions Using Rotational Atherectomy, Cutting-Balloon Angioplasty, or Balloon-Only Angioplasty Before Drug-Eluting Stent Implantation. Journal of Invasive Cardiology, 2017, 29, 378-386.	0.4	8
201	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1349-1357.	2.9	54
202	A Critical Appraisal of Aspirin in Secondary Prevention. Circulation, 2016, 134, 1881-1906.	1.6	70
203	Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction. Circulation, 2016, 134, 1918-1930.	1.6	148
204	Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy. Journal of the American College of Cardiology, 2016, 68, 2733-2744.	2.8	160
205	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2016, 68, 1082-1115.	2.8	1,232
206	Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. American Journal of Cardiology, 2016, 117, 1703-1713.	1.6	18
207	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 674-684.	2.9	51
208	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. Journal of the American College of Cardiology, 2016, 67, 2224-2234.	2.8	445
209	Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. American Journal of Cardiology, 2016, 118, 6-16.	1.6	9
210	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. American Heart Journal, 2016, 182, 125-134.	2.7	108
211	Acute and 30-Day Outcomes in Women After TAVR. JACC: Cardiovascular Interventions, 2016, 9, 1589-1600.	2.9	85
212	Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease. European Heart Journal, 2016, 37, 3440-3447.	2.2	57
213	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 1890-1901.	2.9	32
214	Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. American Journal of Cardiology, 2016, 118, 1661-1668.	1.6	6
215	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. New England Journal of Medicine, 2016, 375, 2423-2434.	27.0	1,265
216	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. New England Journal of Medicine, 2016, 375, 2223-2235.	27.0	843

#	ARTICLE	IF	CITATIONS
217	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACCP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Dis. Circulation, 2016, 134, e123-55.	1.6	1,069
218	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 28-38.	2.9	31
219	Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). American Journal of Cardiology, 2016, 117, 192-200.	1.6	16
220	Gender differences in outcomes in patients with acute coronary syndrome in the current era: A review. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 51-60.	1.0	35
221	Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. American Heart Journal, 2016, 171, 40-47.	2.7	40
222	Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease. Circulation: Cardiovascular Interventions, 2015, 8, e001683.	3.9	65
223	Antithrombotic strategy variability in Atrial fibrillation and obstructive coronary disease revascularized with PCI: rationale and study design of the prospective observational multicenter AVIATOR 2 registry. American Heart Journal, 2015, 170, 1234-1242.	2.7	4
224	Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2015, 66, 2860-2868.	2.8	116
225	Incidence and Impact of Totally Occluded Culprit Coronary Arteries in Patients Presenting With Non-ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2015, 115, 428-433.	1.6	22
226	Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. Journal of the American College of Cardiology, 2015, 65, 1298-1310.	2.8	314
227	An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). American Heart Journal, 2015, 169, 472-478.e5.	2.7	140
228	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or T) on Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2015, 116, 845-852.	1.6	32
229	Gender-specific outcomes after balloon aortic valvuloplasty: In-hospital and long-term outcomes. American Heart Journal, 2015, 170, 180-186.	2.7	11
230	Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). American Journal of Cardiology, 2015, 116, 37-42.	1.6	28
231	Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	46
232	Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2015, 66, 1036-1045.	2.8	344
233	Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes. Circulation: Cardiovascular Interventions, 2015, 8, e002475.	3.9	148
234	Sex, adverse cardiac events, and infarct size in anterior myocardial infarction: An analysis of Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI). American Heart Journal, 2015, 169, 86-93.	2.7	13

#	ARTICLE	IF	CITATIONS
235	The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: A sub-analysis of the BRAVO study. Catheterization and Cardiovascular Interventions, 2014, 83, 148-153.	1.7	16
236	Effect of Anemia on Frequency of Short- and Long-Term Clinical Events in Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). American Journal of Cardiology, 2014, 114, 1823-1829.	1.6	53
237	Body Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 537 American Journal of Cardiology, 2014, 114, 9-16.	1.6	38
238	Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2014, 63, 1845-1854.	2.8	343
239	Association Between Intraprocedural Thrombotic Events and Adverse Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (a Harmonizing) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 537	1.6	32
240	Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 537	1.6	32
241	Meta-Analysis of Randomized Trials Comparing the Effectiveness of Different Strategies for the Treatment of Drug-Eluting Stent Restenosis. American Journal of Cardiology, 2014, 114, 1339-1346.	1.6	30
242	A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches in Women Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 857-867.	2.9	223
243	Prognostic Utility of the SYNTAX Score in Patients With Single Versus Multivessel Disease Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 537	1.6	32
244	Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. EuroIntervention, 2014, 10, 312-319.	3.2	22
245	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, The, 2013, 382, 1714-1722.	13.7	537
246	Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet, The, 2013, 382, 614-623.	13.7	740
247	Consideration of a New Definition of Clinically Relevant Myocardial Infarction After Coronary Revascularization. Journal of the American College of Cardiology, 2013, 62, 1563-1570.	2.8	506
248	Relationship Between Myocardial Reperfusion, Infarct Size, and Mortality. JACC: Cardiovascular Interventions, 2013, 6, 718-724.	2.9	42
249	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet, The, 2013, 382, 1879-1888.	13.7	127
250	Antithrombotic Treatment in Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2013, 62, 2349-2359.	2.8	151
251	Impact of bifurcation target lesion on angiographic, electrocardiographic, and clinical outcomes of patients undergoing primary percutaneous coronary intervention (from the Harmonizing Outcomes) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 537 EuroIntervention. 2013, 9, 817-823.	3.2	17
252	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. European Heart Journal, 2012, 33, 2403-2418.	2.2	900

#	ARTICLE	IF	CITATIONS
253	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). European Journal of Cardio-thoracic Surgery, 2012, 42, S45-S60.	1.4	1,605
254	Operator Versus Core Laboratory Assessment of Angiographic Reperfusion Markers in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segmentâ€Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2012, 5, 563-569.	3.9	10
255	Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention in Patients With Nonâ€ST-Segment Elevation Acute Coronary Syndromes Are Associated With Adverse Outcomes. Journal of the American College of Cardiology, 2012, 59, 1745-1751.	2.8	39
256	Updated Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2012, 60, 1438-1454.	2.8	1,560
257	Drug-Eluting Stent for Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 718-727.	2.9	121
258	Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2012, 5, 1097-1105.	2.9	101
259	Coronary Plaque Composition, Morphology, and Outcomes in Patients With and Without Chronic Kidney Disease Presenting With Acute Coronary Syndromes. JACC: Cardiovascular Imaging, 2012, 5, S53-S61.	5.3	93
260	High Platelet Reactivity on Clopidogrel Therapy Correlates With Increased Coronary Atherosclerosis and Calcification. JACC: Cardiovascular Imaging, 2012, 5, 540-549.	5.3	48
261	Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation Clinical Trials. Journal of the American College of Cardiology, 2011, 57, 253-269.	2.8	735
262	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 58, e44-e122.	2.8	2,027
263	A Prospective Natural-History Study of Coronary Atherosclerosis. New England Journal of Medicine, 2011, 364, 226-235.	27.0	2,721
264	The Academic Research Consortium Governance Charter. JACC: Cardiovascular Interventions, 2011, 4, 595-596.	2.9	33
265	Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 191-197.	2.9	229
266	5-Year Follow-Up of Polytetrafluoroethylene-Covered Stents Compared With Bare-Metal Stents in Aortocoronary Saphenous Vein Grafts. JACC: Cardiovascular Interventions, 2011, 4, 300-309.	2.9	64
267	Impact of Bleeding on Mortality After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 654-664.	2.9	329
268	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. Circulation, 2011, 123, 2736-2747.	1.6	3,378
269	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Circulation, 2011, 124, e574-651.	1.6	1,946
270	Comparison of Bivalirudin Versus Bivalirudin Plus Glycoprotein IIb/IIIa Inhibitor Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Having Percutaneous Intervention for Narrowed Saphenous Vein Aorto-Coronary Grafts (the ACUTY Trial Investigators). American Journal of Cardiology, 2010, 106, 941-945.	1.6	19

#	ARTICLE	IF	CITATIONS
271	In-Stent Restenosis in the Drug-Eluting Stent Era. Journal of the American College of Cardiology, 2010, 56, 1897-1907.	2.8	663
272	A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2010, 55, 2556-2566.	2.8	590
273	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. European Heart Journal, 2009, 30, 1457-1466.	2.2	315
274	Ionic Low-Osmolar Versus Nonionic Iso-Osmolar Contrast Media to Obviate Worsening Nephropathy After Angioplasty in Chronic Renal Failure Patients. JACC: Cardiovascular Interventions, 2009, 2, 415-421.	2.9	62
275	Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction. New England Journal of Medicine, 2009, 360, 1946-1959.	27.0	657
276	Correlations between epicardial flow, microvascular reperfusion, infarct size and clinical outcomes in patients with anterior versus non-anterior myocardial infarction treated with primary or rescue angioplasty: analysis from the EMERALD trial. EuroIntervention, 2009, 5, 417-424.	3.2	13
277	Contrast-induced nephropathy. Catheterization and Cardiovascular Interventions, 2008, 71, 62-72.	1.7	99
278	The Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale. American Heart Journal, 2008, 156, 44-56.	2.7	152
279	Bivalirudin during Primary PCI in Acute Myocardial Infarction. New England Journal of Medicine, 2008, 358, 2218-2230.	27.0	1,693
280	Off-label use of drug-eluting stents: assessing the risk. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 594-595.	3.3	3
281	Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet, The, 2007, 369, 907-919.	13.7	367
282	Clinical End Points in Coronary Stent Trials. Circulation, 2007, 115, 2344-2351.	1.6	4,993
283	Impact of Major Bleeding on 30-Day Mortality and Clinical Outcomes in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2007, 49, 1362-1368.	2.8	776
284	Predictors of Infarct Size After Primary Coronary Angioplasty in Acute Myocardial Infarction from Pooled Analysis from Four Contemporary Trials. American Journal of Cardiology, 2007, 100, 1370-1375.	1.6	125
285	Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: Analysis from the CADILLAC trial. American Heart Journal, 2006, 151, 1231-1238.	2.7	111
286	Can manual thrombus aspiration improve myocardial reperfusion?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 68-69.	3.3	0
287	Bivalirudin for Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2006, 355, 2203-2216.	27.0	1,367
288	Impact and Determinants of Left Ventricular Function in Patients Undergoing Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. American Journal of Cardiology, 2005, 96, 325-331.	1.6	85

#	ARTICLE	IF	CITATIONS
289	Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. Journal of the American College of Cardiology, 2005, 45, 1397-1405.	2.8	451
290	Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction. Circulation, 2005, 111, 1611-1618.	1.6	173
291	Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. American Journal of Cardiology, 2004, 93, 963-968.	1.6	23
292	Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Journal of the American College of Cardiology, 2004, 44, 547-553.	2.8	238
293	Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale. American Heart Journal, 2004, 148, 764-775.	2.7	231
294	A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention. Journal of the American College of Cardiology, 2004, 44, 1393-1399.	2.8	1,127
295	Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. Journal of Invasive Cardiology, 2003, 15, 18-22.	0.4	103
296	Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. Journal of the American College of Cardiology, 2002, 39, 591-597.	2.8	370
297	Influence of gender on early and one-year clinical outcomes after saphenous vein graft stenting. American Journal of Cardiology, 2001, 87, 401-405.	1.6	38
298	Differential Impact on Survival of Electrocardiographic Q-Wave Versus Enzymatic Myocardial Infarction After Percutaneous Intervention. Circulation, 2001, 104, 642-647.	1.6	207
299	Influence of diabetes mellitus on early and late clinical outcomes in saphenous vein graft stenting. Journal of the American College of Cardiology, 2000, 36, 1186-1193.	2.8	24
300	The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. Journal of the American College of Cardiology, 2000, 36, 1542-1548.	2.8	669
301	Percutaneous revascularization of the internal mammary artery graft: short- and long-term outcomes. Journal of the American College of Cardiology, 2000, 35, 944-948.	2.8	57
302	In-hospital and long-term results of stent deployment compared with balloon angioplasty for treatment of narrowing at the saphenous vein graft distal anastomosis site. American Journal of Cardiology, 1999, 84, 1381-1384.	1.6	30
303	The Final Word: Current Strategies for the Lifetime Management of Patients with Aortic Valve Stenosis. US Cardiology Review, 0, 16, .	0.5	0